@blafarm: you wrote: "I believe CytoDyn made a ca

@blafarm: you wrote:
"I believe CytoDyn made a calculated decision preserve capital and slow down the CD12 trial enrollment. While I respect and admire their efforts to manage trial expenses, this strategy makes absolutely no sense in the context of Dr.NP repeatedly claiming that it would be very unlikely for the trial to be halted at the interim analysis. If a trial halt was so improbable at interim analysis -- then why on earth did they slow down enrollment? In my opinion, this represents a bad strategic decision, and one that can be added to other bad decisions rendered this year."

You said Dr Nader P has been.... "repeatedly claiming that it would be very unlikely for the trial to be halted at the Interim analysis" and you also propose that he may have "made a calculated decision (to) preserve capital and slow down the CD12 trial enrollment". Then, you say "In my opinion this represents a bad strategic decision......
I disagree in this way: that combo of events/statements would be much worse than a "bad strategic decision...."
It would be a totally idiodic combo more typical of a child or of a seriously mentally challenged person.
Unless he actually meant unlikley halt at the Inerim analysis due to lack of efficacy????
Otherwise, there won't be a halt and approve so let's slow down enrollment?
That's like cutting both his feet off.
I would much more likely see him slowing enrollment in s/c if he was very confident about either a "halt and approval asap" or at least an EUA.